Healthcare startup Qure.ai has secured $16 million in financing to develop AI-powered medical solutions. Further, the company announced today. Qure.ai's flagship product, qXR, is a low-cost chest X-ray solution that utilizes artificial intelligence to identify critical health markers. This technology is particularly crucial in developing regions with limited access to clinics. Qure.ai aims to obtain regulatory clearances worldwide to make its innovative product widely available.
Back
Qure.ai's CEO, Prashant Warier, expressed pride in the company's achievements, stating that their solutions have already positively impacted patient lives in over 200 locations across 20 countries. Their products significantly reduce the time required for traditional scan interpretation, delivering life-saving treatments even in remote areas. The funding will support further research and development, enabling Qure.ai to expand its solutions and provide accessible and affordable healthcare.
At the core of qXR is an AI model that can analyze X-rays in milliseconds and detect up to 15 common markers, including tuberculosis, COPD, lung malignancies, and certain cardiac disorders. The model was trained using anonymized X-ray scans from medical institutions, amassing a gallery of over 2.5 million images.
Qure.ai also offers qER, an AI-powered CT algorithm that identifies brain hemorrhaging and bone fractures. The company provides cloud-hosted and on-premise clinic installation options, granting radiologists access to a comprehensive workflow management platform.
The funding round was led by Sequoia India, with the participation of MassMutual Ventures Southeast Asia. Qure.ai, founded in 2016 and incubated by Fractal Analytics, has already performed screenings on over 600,000 individuals in 20 countries.
